Lifestyle
- Regular moderate exercise
- Stress management
- Adequate hydration
D-Dimer · Fibrin-Abbauprodukt
D-Dimer quantifies the presence of fibrin degradation products resulting from plasmin-mediated breakdown of cross-linked fibrin.
Ranges can vary based on age and clinical context; age-adjusted cutoffs are often used.
D-Dimer is a fibrin degradation product that emerges from the plasmin-induced breakdown of cross-linked fibrin, serving as a biomarker for coagulation activation and secondary fibrinolysis. Researchers have found it instrumental in ruling out venous thromboembolism (VTE) and assessing the risk of VTE recurrence, as well as determining the optimal duration of anticoagulant therapy. Elevated D-Dimer levels can also indicate various disorders, including disseminated intravascular coagulation, infectious diseases, and cancer. In athletic and biohacking contexts, D-Dimer levels may rise due to strenuous physical activity, reflecting temporary coagulation activation without pathological significance. However, the interpretation of D-Dimer levels must consider confounding factors such as age, pregnancy, and recent exercise. Researchers have observed that preanalytical variables, assay performance, and postanalytical variables like age-adjusted cutoffs can influence D-Dimer measurements. Therefore, standardized testing protocols are crucial for accurate clinical interpretation.
Klinische Bedeutung
Elevated D-Dimer levels suggest active coagulation and fibrinolysis, often associated with conditions like VTE, disseminated intravascular coagulation, and certain cancers. Normal levels help rule out VTE in patients with low clinical probability.
Progressively rising D-Dimer values may indicate increasing thrombotic activity or worsening of an underlying condition. Re-test in 1-2 weeks if clinically indicated.
Falling D-Dimer values suggest resolution of thrombotic activity or effective anticoagulation therapy.
Re-test Interval
4 weeks if outside optimal range
Note:
Consult a healthcare provider before making significant lifestyle changes, especially if on anticoagulation therapy.
Testing Frequency
As clinically indicated, especially in suspected thrombotic events.
Current research suggests that there is a lack of standardization in D-dimer testing and reporting, leading to confusion regarding reference ranges and optimal targets across different populations. Researchers have not yet established the impact of confounding factors such as age, pregnancy, and comorbidities on D-dimer levels in diverse clinical settings. Additionally, unanswered clinical questions include the optimal management strategies for patients with elevated D-dimer levels but no clear thromboembolic events.
1,373
Total Citations
15
Human/RCT
3.5
Avg. Influence
2026
Latest
This study reviewed the various factors affecting D-dimer measurement and its clinical applications. Researchers found that D-dimer is increasingly used to assess VTE recurrence risk and to aid in anticoagulation treatment duration decisions. The review emphasizes the need to consider preanalytical and postanalytical variables when interpreting D-dimer results.
Researchers found that while D-dimer is a sensitive marker for thrombus formation, it can also be elevated in non-thrombotic conditions, affecting its predictive value. The study emphasizes D-dimer's utility in diagnosing and managing various thrombosis-related conditions. The review concludes that D-dimer can safely exclude VTE in symptomatic outpatients when combined with clinical probability assessment.
Researchers conducted a systematic review to evaluate the prognostic value of plasma D-dimer in digestive cancers. They found that elevated D-dimer levels correlate with worse overall survival, particularly in colorectal cancer, suggesting its potential as a biomarker for cancer prognosis.
Halaby Rim, et al. · Journal of thrombosis and thrombolysis · 2015
This study examined the prognostic significance of elevated D-dimer levels in various medical conditions. Researchers found that high D-dimer levels are associated with increased risks of venous thromboembolism and mortality, indicating that patients with elevated D-dimer may require closer monitoring and evaluation.
Key findings
Researchers observed that 14.5% of discharged COVID-19 patients had positive RT-PCR tests again, indicating potential virus recrudescence. The study found correlations between laboratory parameters, treatment duration, and time to illness resolution, suggesting the need for careful monitoring.
This study examined the management of high D-dimer levels in individuals without signs of thrombus formation. Researchers found that elevated D-dimer can arise from various physiological conditions and disorders, necessitating careful evaluation by hematologists. The review emphasizes the importance of understanding the context of elevated D-dimer levels in clinical practice.
This study highlighted the importance of D-dimer testing in acute cardiovascular care. Researchers found that while D-dimer is useful for excluding venous thromboembolic events, the lack of standardized assays necessitates careful interpretation of results in clinical practice.
Researchers found that D-dimer testing has significantly reduced the need for radiological investigations in ruling out VTE. The study discusses the importance of understanding technical issues related to D-dimer testing and the need for harmonization of immunoassays. The review highlights D-dimer's role in diagnosing systemic coagulation disorders, particularly disseminated intravascular coagulation.
This study investigated the correlation between D-dimer levels and outcomes in hospitalized COVID-19 patients. Researchers found that higher admission and peak D-dimer values were associated with increased rates of intubation and mortality. Monitoring D-dimer trends may provide opportunities for early intervention.
Researchers summarized the role of fibrinogen in coagulation and its disorders, which can lead to both bleeding and thrombotic complications. The review discusses laboratory evaluations for fibrinogen disorders and management strategies for congenital and acquired conditions. Key findings include the importance of fibrinogen in clot formation and the need for accurate diagnostic assays.
10
Total Trials
1,746
Total Enrolled
Universitätsklinikum Hamburg-Eppendorf
116
2026
Disease Control Rate Within the First 6 Months of Cemiplimab Treatment
Assiut University
100
2025
Serum CRP level among hemodialysis patients
Al-Nahrain University
112
2025
any episode of VTE (Venous Thromboembolism)
Chinese University of Hong Kong
47
2023
Serum levels of D-Dimer, Aggrecan and Desmosine
Assiut University
90
2020
Measurement of N-terminal pro-B type natriuretic peptide, troponin-I and D-dimer in COVID-19 patients
Assistance Publique - Hôpitaux de Paris
1,000
2020
Measure D-dimers (ng/ml) to study coagulopathy to characterize COVID-19
Ain Shams University
150
2020
Mortality
Wake Forest University Health Sciences
59
2014
Serum D-dimer levels (ug/ml)
University of Vermont
38
2012
To determine if rosuvastatin therapy reduces the risk of VTE in patients with cancer receiving chemotherapy, as measured by a decrease in D-dimer level with treatment compared to placebo
Albert Einstein College of Medicine
34
2010
D-Dimer Levels Than in Black Women With Hb AA and White Women With Hb AA.
Research publications about D-Dimer over time
7totalLog lab results, track trends and optimize your biomarkers over time.
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer